{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:02:17Z","timestamp":1781078537220,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106865","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:19:22Z","timestamp":1763702362000},"page":"106865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["\u201cEffectiveness and associated factors of response to Fampridine in multiple sclerosis: A prospective observational study from an expert center\u201d"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-1546","authenticated-orcid":false,"given":"Elisa","family":"Martinez-Campos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Horno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Castill\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vidal-Jordana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Zabalza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breog\u00e1n","family":"Rodr\u00edguez-Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Vilaseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Arrambide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agust\u00edn","family":"Pappolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Midaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Ari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Mongay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Cobo-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Comabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Tur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Sastre-Garriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tintor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.msard.2025.106865_bib0001","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/brainsci9120357","article-title":"Cortical excitability measures may predict clinical response to fampridine in patients with multiple sclerosis and gait impairment","volume":"9","author":"Ahdab","year":"2019","journal-title":"Brain Sci."},{"issue":"5","key":"10.1016\/j.msard.2025.106865_bib0002","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/nmt-2020-0024","article-title":"Efficacy and safety of fampridine for walking disability in multiple sclerosis","volume":"10","author":"Arp\u00edn","year":"2020","journal-title":"Neurodegener. Dis. Manag"},{"key":"10.1016\/j.msard.2025.106865_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104424","article-title":"Mobility and balance rehabilitation in multiple sclerosis: a systematic review and dose-response meta-analysis","volume":"69","author":"Corrini","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106865_bib0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clim.2011.06.004","article-title":"Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation","volume":"142","author":"Espejo","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106865_bib0006","unstructured":"European Medicines Agency. Fampyra Summary of Product Characteristics, European Medicines Agency (EMA). 2018. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fampyra."},{"issue":"2","key":"10.1016\/j.msard.2025.106865_bib0007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/ene.13805","article-title":"Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis","volume":"26","author":"Filli","year":"2019","journal-title":"Eur. J. Neurol."},{"issue":"9665","key":"10.1016\/j.msard.2025.106865_bib0009","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.msard.2025.106865_bib0008","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended-release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106865_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7224\/1537-2073.2013-023","article-title":"A pooled analysis of two phase 3 clinical trials of dalfampridine in patients with multiple sclerosis","volume":"16","author":"Goodman","year":"2014","journal-title":"Int. J. MS Care"},{"issue":"1","key":"10.1016\/j.msard.2025.106865_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-item MS walking scale (MSWS-12)","volume":"60","author":"Hobart","year":"2003","journal-title":"Neurology."},{"issue":"16","key":"10.1016\/j.msard.2025.106865_bib0011","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1212\/WNL.0b013e31828cf7f3","article-title":"Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS","volume":"80","author":"Hobart","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106865_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221090398","article-title":"Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE","volume":"15","author":"Hupperts","year":"2022","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"14","key":"10.1016\/j.msard.2025.106865_bib0014","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1177\/1352458514533844","article-title":"Changes in cognition, arm function and lower body function after slow-release fampridine treatment","volume":"20","author":"Jensen","year":"2014","journal-title":"Mult Scler J"},{"issue":"3","key":"10.1016\/j.msard.2025.106865_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/ejhpharm-2016-001129","article-title":"Impact of fampridine on quality of life: clinical benefit in real-world practice","volume":"25","author":"Marzal-Alfaro","year":"2018","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"2","key":"10.1016\/j.msard.2025.106865_bib0016","first-page":"283","article-title":"Assessment of the efficacy and safety of fampridine","volume":"41","author":"Mejuto","year":"2017","journal-title":"Farm. Hosp."},{"key":"10.1016\/j.msard.2025.106865_bib0003","first-page":"75","article-title":"Assessing the long-term clinical benefit of prolonged-release fampridine tablets in a real-world setting: a review of 67 cases","volume":"4","author":"Prugger","year":"2013","journal-title":"Patient Relat. Outcome Meas."},{"issue":"5","key":"10.1016\/j.msard.2025.106865_bib0017","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nrl.2015.11.013","article-title":"Guideline for the treatment of gait impairment with prolonged-release fampridine (Fampyra\u00ae) in patients with multiple sclerosis","volume":"33","author":"Rami\u00f3-Torrent\u00e0","year":"2018","journal-title":"Neurologia"},{"issue":"10","key":"10.1016\/j.msard.2025.106865_bib0018","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1177\/1352458517720043","article-title":"Fampridine response in MS patients with gait impairment in a real-world setting: need for new response criteria?","volume":"24","author":"Rodriguez-Leal","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106865_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104034","article-title":"Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis: an interventional follow-up study","volume":"66","author":"Skov","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106865_bib0020","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/jnnp-2013-306860","article-title":"Central motor conduction time may predict response to fampridine in patients with multiple sclerosis","volume":"85","author":"Zeller","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:31:34Z","timestamp":1781076694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":20,"alternative-id":["S2211034825006078"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106865","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cEffectiveness and associated factors of response to Fampridine in multiple sclerosis: A prospective observational study from an expert center\u201d","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106865"}}